FluoGuide A/S (SE:FLUO)
:FLUO
Want to see SE:FLUO full AI Analyst Report?
FLUO Stock Chart & Stats
kr36.00
-kr1.70(-3.82%)
At close: 4:00 PM EST
kr36.00
-kr1.70(-3.82%)
Day’s Range― - ―
52-Week Rangekr28.00 - kr47.80
Previous CloseN/A
Volume5.01K
Average Volume (3M)8.21K
Market Cap
kr734.08M
Enterprise Valuekr427.89M
Total Cash (Recent Filing)kr63.24M
Total Debt (Recent Filing)kr27.93M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.89
Shares Outstanding16,349,314
10 Day Avg. Volume11,579
30 Day Avg. Volume8,206
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)6.10
Price to Sales (P/S)0.00
P/FCF Ratio-8.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet BufferThe balance sheet still shows positive shareholders' equity (43.1m TTM) and a moderate debt-to-equity profile (~0.52x), providing tangible financial flexibility. This cushion supports continued R&D and trial activity over months, reducing immediate insolvency risk while the company pursues commercialization.
Focused Clinical PlatformFluoGuide’s clear strategic focus on fluorescence-guided surgery and targeted imaging agents is a durable business-model strength. A concentrated product thesis in surgical oncology can create clinical differentiation and adoption pathways with surgeons and hospitals, supporting longer-term commercial potential if clinical milestones succeed.
Improving Cash-burn TrendReported free cash flow has become less negative versus the 2025 annual period, indicating a modest improvement in cash efficiency. If sustained, this trend reduces the pace of runway depletion, lowers near-term external funding needs, and improves the company's ability to advance clinical programs without immediate dilutive financing.
Bears Say
Material Cash BurnThe company is generating materially negative operating and free cash flow (TTM OCF ~-42.1m; FCF ~-37.5m). Persistent large cash burn erodes runway and forces reliance on external capital, which can dilute existing shareholders and distract management from long-term execution if financing becomes frequent or costly.
Minimal, Volatile RevenueRevenue has been negligible and volatile (zero in 2025 annual; TTM only 57k vs 385k in 2024), signaling limited commercial traction. This lack of stable sales undermines the company's ability to scale margins and fund operations internally, making sustained profitability reliant on achieving successful commercialization or external funding.
Ongoing Losses Eroding EquityShareholders' equity has declined markedly (54.6m to 43.1m) as losses accumulate and returns remain strongly negative. Continued equity erosion constrains strategic options, increases vulnerability to adverse funding conditions, and signals that without a clear path to revenue and profit, the company may need dilutive capital or restructuring.
FluoGuide A/S News
FLUO FAQ
What was FluoGuide A/S’s price range in the past 12 months?
FluoGuide A/S lowest stock price was kr28.00 and its highest was kr47.80 in the past 12 months.
What is FluoGuide A/S’s market cap?
FluoGuide A/S’s market cap is kr734.08M.
When is FluoGuide A/S’s upcoming earnings report date?
FluoGuide A/S’s upcoming earnings report date is Aug 25, 2026 which is in 64 days.
How were FluoGuide A/S’s earnings last quarter?
FluoGuide A/S released its earnings results on May 27, 2026. The company reported -kr1.032 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.032.
Is FluoGuide A/S overvalued?
According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued.
Does FluoGuide A/S pay dividends?
FluoGuide A/S does not currently pay dividends.
What is FluoGuide A/S’s EPS estimate?
FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FluoGuide A/S have?
FluoGuide A/S has 16,349,314 shares outstanding.
What happened to FluoGuide A/S’s price movement after its last earnings report?
FluoGuide A/S reported an EPS of -kr1.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.687%.
Which hedge fund is a major shareholder of FluoGuide A/S?
Currently, no hedge funds are holding shares in SE:FLUO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FluoGuide A/S
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.
Technical Analysis
Q-linea AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Guard Therapeutics International AB
―
Nanexa AB
―